{"transactions":[{"id":793610,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":49925,"kind":"person","name":"Katkin Keith","position":1,"cik":"0001314596","reported_name":"Katkin Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2026-05-04T21:29:30.000Z","date":"2026-04-30","kind":"grant","planned":true,"acquired":true,"shares":11296,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F5","text":"The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant."}],"balance_after":11296,"derivative":{"exercise_price":7.99,"expiration_date":"2033-04-30","underlying":"Common Stock","underlying_shares":11296},"source":{"system":"sec-edgar","filing":"0001314596-26-000002","document":"wk-form4_1777930168.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1314596/000131459626000002/wk-form4_1777930168.xml","form_type":"4"}},{"id":793609,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":49925,"kind":"person","name":"Katkin Keith","position":1,"cik":"0001314596","reported_name":"Katkin Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-04T21:29:30.000Z","date":"2026-04-30","kind":"sale","planned":true,"acquired":false,"shares":15481,"price":8.28,"value":128182.68,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares sold by the Reporting Person. Shares were sold pursuant to a Rule 10b5-1 trading plan, dated November 10, 2025, for the purpose of satisfying tax obligations relating to the vesting of RSUs on April 29, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price for sales executed on the same day within a one-dollar price range. These shares were sold in multiple transactions at prices ranging from $8.23 to $8.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":96294,"source":{"system":"sec-edgar","filing":"0001314596-26-000002","document":"wk-form4_1777930168.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1314596/000131459626000002/wk-form4_1777930168.xml","form_type":"4"}},{"id":793608,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":49925,"kind":"person","name":"Katkin Keith","position":1,"cik":"0001314596","reported_name":"Katkin Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-04T21:29:30.000Z","date":"2026-04-30","kind":"grant","planned":true,"acquired":true,"shares":25344,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an annual grant of restricted stock units (\"RSUs\") granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the \"Company\") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date (\"Annual Grant Vesting Date\"), subject to the Reporting Person remaining a member of the Company's board of directors through the Annual Grant Vesting Date."}],"balance_after":111775,"source":{"system":"sec-edgar","filing":"0001314596-26-000002","document":"wk-form4_1777930168.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314596/000131459626000002/wk-form4_1777930168.xml","form_type":"4"}},{"id":915846,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":49925,"kind":"person","name":"Katkin Keith","position":1,"cik":"0001314596","reported_name":"Katkin Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-06T21:13:08.000Z","date":"2026-02-04","kind":"grant","planned":false,"acquired":true,"shares":24000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control."}],"balance_after":124000,"source":{"system":"sec-edgar","filing":"0001193125-26-041192","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314596/000119312526041192/ownership.xml","form_type":"4"}},{"id":937080,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":49925,"kind":"person","name":"Katkin Keith","position":1,"cik":"0001314596","reported_name":"Katkin Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-01-16T22:00:06.000Z","date":"2026-01-10","kind":"exercise","planned":false,"acquired":false,"shares":8575,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents shares issuable on settlement of restricted stock units (\"RSUs\") for common stock on a one-for-one basis granted to the reporting person. The RSUs were issued on January 10, 2025 and vested 100% on January 10, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents shares issuable on settlement of restricted stock units (\"RSUs\") for common stock on a one-for-one basis granted to the reporting person. The RSUs were issued on January 10, 2025 and vested 100% on January 10, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents shares issuable on settlement of restricted stock units (\"RSUs\") for common stock on a one-for-one basis granted to the reporting person. The RSUs were issued on January 10, 2025 and vested 100% on January 10, 2026."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":8575},"source":{"system":"sec-edgar","filing":"0001193125-26-015486","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1404281/000119312526015486/ownership.xml","form_type":"4"}},{"id":937079,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":49925,"kind":"person","name":"Katkin Keith","position":1,"cik":"0001314596","reported_name":"Katkin Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-16T22:00:06.000Z","date":"2026-01-10","kind":"exercise","planned":false,"acquired":true,"shares":8575,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares issuable on settlement of restricted stock units (\"RSUs\") for common stock on a one-for-one basis granted to the reporting person. The RSUs were issued on January 10, 2025 and vested 100% on January 10, 2026."}],"balance_after":8575,"source":{"system":"sec-edgar","filing":"0001193125-26-015486","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404281/000119312526015486/ownership.xml","form_type":"4"}},{"id":1131649,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":49925,"kind":"person","name":"Katkin Keith","position":1,"cik":"0001314596","reported_name":"Katkin Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-28T20:08:23.000Z","date":"2025-05-23","kind":"sale","planned":true,"acquired":false,"shares":7844,"price":6.3,"value":49417.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares sold by the Reporting Person. Shares were sold pursuant to a Rule 10b5-1 trading plan, dated November 8, 2024, for the purpose of satisfying tax obligations relating to the vesting of RSUs on May 22, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"For reporting purposes, sales prices within a $1 range have been aggregated and the weighted average sales price has been reported. The price ranges were: $6.22 - $6.35. The Company maintains a record of the transactions and copies will be provided upon request."}],"balance_after":86431,"source":{"system":"sec-edgar","filing":"0001367644-25-000136","document":"wk-form4_1748462897.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314596/000136764425000136/wk-form4_1748462897.xml","form_type":"4"}},{"id":1142187,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":49925,"kind":"person","name":"Katkin Keith","position":1,"cik":"0001314596","reported_name":"Katkin Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-19T20:01:06.000Z","date":"2025-05-19","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":9.112,"value":91120.0,"ownership":{"direct":true},"balance_after":100000,"source":{"system":"sec-edgar","filing":"0000950170-25-074289","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314596/000095017025074289/ownership.xml","form_type":"4"}},{"id":1160857,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":49925,"kind":"person","name":"Katkin Keith","position":1,"cik":"0001314596","reported_name":"Katkin Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-03T00:30:49.000Z","date":"2025-04-30","kind":"grant","planned":false,"acquired":true,"shares":15824,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant."}],"balance_after":41572,"derivative":{"exercise_price":5.45,"expiration_date":"2032-04-29","underlying":"Common Stock","underlying_shares":15824},"source":{"system":"sec-edgar","filing":"0001367644-25-000106","document":"wk-form4_1746232243.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1314596/000136764425000106/wk-form4_1746232243.xml","form_type":"4"}},{"id":1160856,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":49925,"kind":"person","name":"Katkin Keith","position":1,"cik":"0001314596","reported_name":"Katkin Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-03T00:30:49.000Z","date":"2025-04-30","kind":"grant","planned":false,"acquired":true,"shares":34403,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an annual grant of restricted stock units (\"RSUs\") granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the \"Company\") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date (\"Annual Grant Vesting Date\"), subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date."}],"balance_after":94275,"source":{"system":"sec-edgar","filing":"0001367644-25-000106","document":"wk-form4_1746232243.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314596/000136764425000106/wk-form4_1746232243.xml","form_type":"4"}},{"id":1278523,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":49925,"kind":"person","name":"Katkin Keith","position":1,"cik":"0001314596","reported_name":"Katkin Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-02-07T21:37:19.000Z","date":"2025-02-05","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control."}],"balance_after":90000,"source":{"system":"sec-edgar","filing":"0000950170-25-016363","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314596/000095017025016363/ownership.xml","form_type":"4"}},{"id":1304240,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":49925,"kind":"person","name":"Katkin Keith","position":1,"cik":"0001314596","reported_name":"Katkin Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-01-13T22:30:07.000Z","date":"2025-01-10","kind":"grant","planned":false,"acquired":true,"shares":8575,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's common stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"100% of the restricted stock units will vest on January 10, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"100% of the restricted stock units will vest on January 10, 2026."}],"balance_after":8575,"derivative":{"underlying":"Common Stock","underlying_shares":8575},"source":{"system":"sec-edgar","filing":"0000950170-25-004922","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1404281/000095017025004922/ownership.xml","form_type":"4"}},{"id":1304239,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":49925,"kind":"person","name":"Katkin Keith","position":1,"cik":"0001314596","reported_name":"Katkin Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-01-13T22:30:07.000Z","date":"2025-01-10","kind":"grant","planned":false,"acquired":true,"shares":77175,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase up to 77,175 shares of common stock, which option vests with respect to 100% of the total number of shares on January 10, 2026."}],"balance_after":77175,"derivative":{"exercise_price":4.04,"expiration_date":"2035-01-10","underlying":"Common Stock","underlying_shares":77175},"source":{"system":"sec-edgar","filing":"0000950170-25-004922","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404281/000095017025004922/ownership.xml","form_type":"4"}},{"id":1500100,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":49925,"kind":"person","name":"Katkin Keith","position":1,"cik":"0001314596","reported_name":"Katkin Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-29T01:41:29.000Z","date":"2024-05-23","kind":"grant","planned":false,"acquired":true,"shares":25748,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"The number of options granted was determined by dividing half of the total non-employee director compensation value by the Black-Scholes value of a single option calculated as of the date of the grant."}],"balance_after":25748,"derivative":{"exercise_price":5.02,"expiration_date":"2031-05-22","underlying":"Common Stock","underlying_shares":25748},"source":{"system":"sec-edgar","filing":"0001367644-24-000089","document":"wk-form4_1716946880.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1314596/000136764424000089/wk-form4_1716946880.xml","form_type":"4"}},{"id":1500099,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":49925,"kind":"person","name":"Katkin Keith","position":1,"cik":"0001314596","reported_name":"Katkin Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-29T01:41:29.000Z","date":"2024-05-23","kind":"grant","planned":false,"acquired":true,"shares":17430,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an annual grant of restricted stock units (\"RSUs\") granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the \"Company\") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date (\"Annual Grant Vesting Date\"), subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date."}],"balance_after":59872,"source":{"system":"sec-edgar","filing":"0001367644-24-000089","document":"wk-form4_1716946880.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314596/000136764424000089/wk-form4_1716946880.xml","form_type":"4"}},{"id":1651351,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":49925,"kind":"person","name":"Katkin Keith","position":1,"cik":"0001314596","reported_name":"Katkin Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-02-09T21:04:33.000Z","date":"2024-02-07","kind":"grant","planned":false,"acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control."}],"balance_after":65000,"source":{"system":"sec-edgar","filing":"0001562180-24-001218","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314596/000156218024001218/primarydocument.xml","form_type":"4"}},{"id":1874456,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":49925,"kind":"person","name":"Katkin Keith","position":1,"cik":"0001314596","reported_name":"Katkin Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-30T23:05:11.000Z","date":"2023-05-25","kind":"grant","planned":false,"acquired":true,"shares":33847,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of restricted stock units granted under the company's Stock Incentive Plan, as amended and restated. These restricted stock units vest in one installment beginning on the day prior to the first anniversary of the date of grant assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement."}],"balance_after":42442,"source":{"system":"sec-edgar","filing":"0001367644-23-000105","document":"wk-form4_1685487901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314596/000136764423000105/wk-form4_1685487901.xml","form_type":"4"}},{"id":1908124,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":49925,"kind":"person","name":"Katkin Keith","position":1,"cik":"0001314596","reported_name":"Katkin Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-05-02T22:45:57.000Z","date":"2023-05-01","kind":"grant","planned":false,"acquired":true,"shares":752185,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase up to 752,185 shares of Common Stock, which option vests with respect to 376,093 shares on May 1, 2024 and with respect to 376,092 shares on May 1, 2025."}],"balance_after":752185,"derivative":{"exercise_price":2.3,"expiration_date":"2033-05-01","underlying":"Common Stock","underlying_shares":752185},"source":{"system":"sec-edgar","filing":"0001209191-23-026728","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404281/000120919123026728/doc4.xml","form_type":"4"}},{"id":2032459,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":49925,"kind":"person","name":"Katkin Keith","position":1,"cik":"0001314596","reported_name":"Katkin Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-02-03T21:52:54.000Z","date":"2023-02-02","kind":"grant","acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control."}],"balance_after":48000,"source":{"system":"sec-edgar","filing":"0001562180-23-000943","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314596/000156218023000943/primarydocument.xml","form_type":"4"}},{"id":2035744,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":49925,"kind":"person","name":"Katkin Keith","position":1,"cik":"0001314596","reported_name":"Katkin Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-02-02T23:04:04.000Z","date":"2023-02-01","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase up to 20,000 shares of Common Stock, which option vests with respect to 100% of the total number of shares on 2/1/2024."}],"balance_after":20000,"derivative":{"exercise_price":3.08,"expiration_date":"2033-02-01","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-23-006339","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404281/000120919123006339/doc4.xml","form_type":"4"}},{"id":2140271,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":49925,"kind":"person","name":"Katkin Keith","position":1,"cik":"0001314596","reported_name":"Katkin Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2022-10-07T20:05:22.000Z","date":"2022-10-06","kind":"exercise","acquired":false,"shares":20782,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":7.88,"expiration_date":"2029-06-10","underlying":"Common Stock","underlying_shares":20782},"source":{"system":"sec-edgar","filing":"0001562180-22-007125","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1314596/000156218022007125/primarydocument.xml","form_type":"4"}},{"id":2140270,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":49925,"kind":"person","name":"Katkin Keith","position":1,"cik":"0001314596","reported_name":"Katkin Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2022-10-07T20:05:22.000Z","date":"2022-10-06","kind":"exercise","acquired":false,"shares":9117,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":8.93,"expiration_date":"2028-05-23","underlying":"Common Stock","underlying_shares":9117},"source":{"system":"sec-edgar","filing":"0001562180-22-007125","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1314596/000156218022007125/primarydocument.xml","form_type":"4"}},{"id":2140269,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":49925,"kind":"person","name":"Katkin Keith","position":1,"cik":"0001314596","reported_name":"Katkin Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-07T20:05:22.000Z","date":"2022-10-06","kind":"sale","acquired":false,"shares":9117,"price":25.9009,"value":236138.5053,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person.   Following the sales reported in this Form 4, the Reporting Person has a total of 73,000 options to purchase shares of common stock that are vested and immediately exercisable and there are no options to purchase shares of common stock that have not yet vested."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale prices ranged from $25.0000 to $26.4600."}],"balance_after":32000,"source":{"system":"sec-edgar","filing":"0001562180-22-007125","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1314596/000156218022007125/primarydocument.xml","form_type":"4"}},{"id":2140268,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":49925,"kind":"person","name":"Katkin Keith","position":1,"cik":"0001314596","reported_name":"Katkin Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-07T20:05:22.000Z","date":"2022-10-06","kind":"exercise","acquired":true,"shares":9117,"price":8.93,"value":81414.81,"ownership":{"direct":true},"balance_after":41117,"source":{"system":"sec-edgar","filing":"0001562180-22-007125","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1314596/000156218022007125/primarydocument.xml","form_type":"4"}},{"id":2140267,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":49925,"kind":"person","name":"Katkin Keith","position":1,"cik":"0001314596","reported_name":"Katkin Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-07T20:05:22.000Z","date":"2022-10-06","kind":"sale","acquired":false,"shares":20782,"price":25.9009,"value":538272.5038,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person.   Following the sales reported in this Form 4, the Reporting Person has a total of 73,000 options to purchase shares of common stock that are vested and immediately exercisable and there are no options to purchase shares of common stock that have not yet vested."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale prices ranged from $25.0000 to $26.4600."}],"balance_after":32000,"source":{"system":"sec-edgar","filing":"0001562180-22-007125","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1314596/000156218022007125/primarydocument.xml","form_type":"4"}},{"id":2140266,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":49925,"kind":"person","name":"Katkin Keith","position":1,"cik":"0001314596","reported_name":"Katkin Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-07T20:05:22.000Z","date":"2022-10-06","kind":"exercise","acquired":true,"shares":20782,"price":7.88,"value":163762.16,"ownership":{"direct":true},"balance_after":52782,"source":{"system":"sec-edgar","filing":"0001562180-22-007125","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314596/000156218022007125/primarydocument.xml","form_type":"4"}},{"id":2143941,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":49925,"kind":"person","name":"Katkin Keith","position":1,"cik":"0001314596","reported_name":"Katkin Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2022-10-04T21:49:07.000Z","date":"2022-10-04","kind":"exercise","acquired":false,"shares":137,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":7.88,"expiration_date":"2029-06-10","underlying":"Common Stock","underlying_shares":137},"source":{"system":"sec-edgar","filing":"0001562180-22-007011","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1314596/000156218022007011/primarydocument.xml","form_type":"4"}},{"id":2143940,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":49925,"kind":"person","name":"Katkin Keith","position":1,"cik":"0001314596","reported_name":"Katkin Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2022-10-04T21:49:07.000Z","date":"2022-10-04","kind":"exercise","acquired":false,"shares":223,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":8.93,"expiration_date":"2028-05-23","underlying":"Common Stock","underlying_shares":223},"source":{"system":"sec-edgar","filing":"0001562180-22-007011","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1314596/000156218022007011/primarydocument.xml","form_type":"4"}},{"id":2143939,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":49925,"kind":"person","name":"Katkin Keith","position":1,"cik":"0001314596","reported_name":"Katkin Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2022-10-04T21:49:07.000Z","date":"2022-10-03","kind":"exercise","acquired":false,"shares":167,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":7.88,"expiration_date":"2029-06-10","underlying":"Common Stock","underlying_shares":167},"source":{"system":"sec-edgar","filing":"0001562180-22-007011","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1314596/000156218022007011/primarydocument.xml","form_type":"4"}},{"id":2143938,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":49925,"kind":"person","name":"Katkin Keith","position":1,"cik":"0001314596","reported_name":"Katkin Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2022-10-04T21:49:07.000Z","date":"2022-10-03","kind":"exercise","acquired":false,"shares":13,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":8.93,"expiration_date":"2028-05-23","underlying":"Common Stock","underlying_shares":13},"source":{"system":"sec-edgar","filing":"0001562180-22-007011","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1314596/000156218022007011/primarydocument.xml","form_type":"4"}},{"id":2143937,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":49925,"kind":"person","name":"Katkin Keith","position":1,"cik":"0001314596","reported_name":"Katkin Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2022-10-04T21:49:07.000Z","date":"2022-09-30","kind":"exercise","acquired":false,"shares":2914,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":7.88,"expiration_date":"2029-06-10","underlying":"Common Stock","underlying_shares":2914},"source":{"system":"sec-edgar","filing":"0001562180-22-007011","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1314596/000156218022007011/primarydocument.xml","form_type":"4"}},{"id":2143936,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":49925,"kind":"person","name":"Katkin Keith","position":1,"cik":"0001314596","reported_name":"Katkin Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2022-10-04T21:49:07.000Z","date":"2022-09-30","kind":"exercise","acquired":false,"shares":647,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":8.93,"expiration_date":"2028-05-23","underlying":"Common Stock","underlying_shares":647},"source":{"system":"sec-edgar","filing":"0001562180-22-007011","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1314596/000156218022007011/primarydocument.xml","form_type":"4"}},{"id":2143935,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":49925,"kind":"person","name":"Katkin Keith","position":1,"cik":"0001314596","reported_name":"Katkin Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-04T21:49:07.000Z","date":"2022-10-04","kind":"sale","acquired":false,"shares":223,"price":25,"value":5575.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 102,899 options to purchase shares of common stock that are vested and immediately exercisable and there are no options to purchase shares of common stock that have not yet vested."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The sale price was $25.00."}],"balance_after":32000,"source":{"system":"sec-edgar","filing":"0001562180-22-007011","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1314596/000156218022007011/primarydocument.xml","form_type":"4"}},{"id":2143934,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":49925,"kind":"person","name":"Katkin Keith","position":1,"cik":"0001314596","reported_name":"Katkin Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-04T21:49:07.000Z","date":"2022-10-04","kind":"exercise","acquired":true,"shares":223,"price":8.93,"value":1991.39,"ownership":{"direct":true},"balance_after":32223,"source":{"system":"sec-edgar","filing":"0001562180-22-007011","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1314596/000156218022007011/primarydocument.xml","form_type":"4"}},{"id":2143933,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":49925,"kind":"person","name":"Katkin Keith","position":1,"cik":"0001314596","reported_name":"Katkin Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-04T21:49:07.000Z","date":"2022-10-04","kind":"sale","acquired":false,"shares":137,"price":25,"value":3425.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 102,899 options to purchase shares of common stock that are vested and immediately exercisable and there are no options to purchase shares of common stock that have not yet vested."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The sale price was $25.00."}],"balance_after":32000,"source":{"system":"sec-edgar","filing":"0001562180-22-007011","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1314596/000156218022007011/primarydocument.xml","form_type":"4"}},{"id":2143932,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":49925,"kind":"person","name":"Katkin Keith","position":1,"cik":"0001314596","reported_name":"Katkin Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-04T21:49:07.000Z","date":"2022-10-04","kind":"exercise","acquired":true,"shares":137,"price":7.88,"value":1079.56,"ownership":{"direct":true},"balance_after":32137,"source":{"system":"sec-edgar","filing":"0001562180-22-007011","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1314596/000156218022007011/primarydocument.xml","form_type":"4"}},{"id":2143931,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":49925,"kind":"person","name":"Katkin Keith","position":1,"cik":"0001314596","reported_name":"Katkin Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-04T21:49:07.000Z","date":"2022-10-03","kind":"sale","acquired":false,"shares":13,"price":25,"value":325.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 102,899 options to purchase shares of common stock that are vested and immediately exercisable and there are no options to purchase shares of common stock that have not yet vested."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The sale price was $25.00."}],"balance_after":32000,"source":{"system":"sec-edgar","filing":"0001562180-22-007011","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1314596/000156218022007011/primarydocument.xml","form_type":"4"}},{"id":2143930,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":49925,"kind":"person","name":"Katkin Keith","position":1,"cik":"0001314596","reported_name":"Katkin Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-04T21:49:07.000Z","date":"2022-10-03","kind":"exercise","acquired":true,"shares":13,"price":8.93,"value":116.09,"ownership":{"direct":true},"balance_after":32013,"source":{"system":"sec-edgar","filing":"0001562180-22-007011","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1314596/000156218022007011/primarydocument.xml","form_type":"4"}},{"id":2143929,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":49925,"kind":"person","name":"Katkin Keith","position":1,"cik":"0001314596","reported_name":"Katkin Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-04T21:49:07.000Z","date":"2022-10-03","kind":"sale","acquired":false,"shares":167,"price":25,"value":4175.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 102,899 options to purchase shares of common stock that are vested and immediately exercisable and there are no options to purchase shares of common stock that have not yet vested."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The sale price was $25.00."}],"balance_after":32000,"source":{"system":"sec-edgar","filing":"0001562180-22-007011","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1314596/000156218022007011/primarydocument.xml","form_type":"4"}},{"id":2143928,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":49925,"kind":"person","name":"Katkin Keith","position":1,"cik":"0001314596","reported_name":"Katkin Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-04T21:49:07.000Z","date":"2022-10-03","kind":"exercise","acquired":true,"shares":167,"price":7.88,"value":1315.96,"ownership":{"direct":true},"balance_after":32167,"source":{"system":"sec-edgar","filing":"0001562180-22-007011","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1314596/000156218022007011/primarydocument.xml","form_type":"4"}},{"id":2143927,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":49925,"kind":"person","name":"Katkin Keith","position":1,"cik":"0001314596","reported_name":"Katkin Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-04T21:49:07.000Z","date":"2022-09-30","kind":"sale","acquired":false,"shares":647,"price":25.0707,"value":16220.7429,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 102,899 options to purchase shares of common stock that are vested and immediately exercisable and there are no options to purchase shares of common stock that have not yet vested."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale prices ranged from $25.00 to $25.215."}],"balance_after":32000,"source":{"system":"sec-edgar","filing":"0001562180-22-007011","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1314596/000156218022007011/primarydocument.xml","form_type":"4"}},{"id":2143926,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":49925,"kind":"person","name":"Katkin Keith","position":1,"cik":"0001314596","reported_name":"Katkin Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-04T21:49:07.000Z","date":"2022-09-30","kind":"exercise","acquired":true,"shares":647,"price":8.93,"value":5777.71,"ownership":{"direct":true},"balance_after":32647,"source":{"system":"sec-edgar","filing":"0001562180-22-007011","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1314596/000156218022007011/primarydocument.xml","form_type":"4"}},{"id":2143925,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":49925,"kind":"person","name":"Katkin Keith","position":1,"cik":"0001314596","reported_name":"Katkin Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-04T21:49:07.000Z","date":"2022-09-30","kind":"sale","acquired":false,"shares":2914,"price":25.0707,"value":73056.0198,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 102,899 options to purchase shares of common stock that are vested and immediately exercisable and there are no options to purchase shares of common stock that have not yet vested."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale prices ranged from $25.00 to $25.215."}],"balance_after":32000,"source":{"system":"sec-edgar","filing":"0001562180-22-007011","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1314596/000156218022007011/primarydocument.xml","form_type":"4"}},{"id":2143924,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":49925,"kind":"person","name":"Katkin Keith","position":1,"cik":"0001314596","reported_name":"Katkin Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-04T21:49:07.000Z","date":"2022-09-30","kind":"exercise","acquired":true,"shares":2914,"price":7.88,"value":22962.32,"ownership":{"direct":true},"balance_after":34914,"source":{"system":"sec-edgar","filing":"0001562180-22-007011","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314596/000156218022007011/primarydocument.xml","form_type":"4"}},{"id":2303836,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":49925,"kind":"person","name":"Katkin Keith","position":1,"cik":"0001314596","reported_name":"Katkin Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-04-05T20:22:49.000Z","date":"2022-04-02","kind":"grant","acquired":true,"shares":8595,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of restricted stock units granted under the company's Stock Incentive Plan. These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement."}],"balance_after":8595,"source":{"system":"sec-edgar","filing":"0001367644-22-000061","document":"wf-form4_164919014507684.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314596/000136764422000061/wf-form4_164919014507684.xml","form_type":"4"}},{"id":2413194,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":49925,"kind":"person","name":"Katkin Keith","position":1,"cik":"0001314596","reported_name":"Katkin Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-02-03T22:30:46.000Z","date":"2022-02-02","kind":"grant","acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control."}],"balance_after":32000,"source":{"system":"sec-edgar","filing":"0001562180-22-001074","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314596/000156218022001074/primarydocument.xml","form_type":"4"}},{"id":2416280,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":49925,"kind":"person","name":"Katkin Keith","position":1,"cik":"0001314596","reported_name":"Katkin Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-02-02T22:30:16.000Z","date":"2022-02-01","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase up to 20,000 shares of Common Stock, which option vests with respect to 100% of the total number of shares on 2/1/2023."}],"balance_after":20000,"derivative":{"exercise_price":3.97,"expiration_date":"2032-02-01","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-22-006466","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404281/000120919122006466/doc4.xml","form_type":"4"}},{"id":2701344,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":49925,"kind":"person","name":"Katkin Keith","position":1,"cik":"0001314596","reported_name":"Katkin Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-22T00:57:44.000Z","date":"2021-05-19","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares vest monthly over one (1) year from the date of grant subject to the reporting person's continuous service on the Company's Board of Directors."}],"balance_after":30000,"derivative":{"exercise_price":3.64,"expiration_date":"2031-05-19","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001179110-21-005767","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000117911021005767/edgar.xml","form_type":"4"}},{"id":2701343,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":49925,"kind":"person","name":"Katkin Keith","position":1,"cik":"0001314596","reported_name":"Katkin Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-22T00:57:44.000Z","date":"2021-05-19","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the reporting person's continuous service on the Company's Board of Directors."}],"balance_after":25000,"source":{"system":"sec-edgar","filing":"0001179110-21-005767","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000117911021005767/edgar.xml","form_type":"4"}},{"id":2876431,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":49925,"kind":"person","name":"Katkin Keith","position":1,"cik":"0001314596","reported_name":"Katkin Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-05T21:18:10.000Z","date":"2021-02-03","kind":"grant","acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units that vests one year from the date of grant.  The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control."}],"balance_after":16000,"source":{"system":"sec-edgar","filing":"0001562180-21-000927","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314596/000156218021000927/primarydocument.xml","form_type":"4"}},{"id":3031235,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":49925,"kind":"person","name":"Katkin Keith","position":1,"cik":"0001314596","reported_name":"Katkin Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-09-16T00:10:40.000Z","date":"2020-09-11","kind":"grant","acquired":true,"shares":5907.15,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 5,907.15 shares of the Issuer's Series X1 Convertible Preferred Stock, which will vest in equal monthly installments over two years, subject to the Reporting Person's continued service to the Issuer through each vesting date. The Reporting Person's ability to exercise the option will be subject to stockholder approval under Nasdaq Marketplace Rule 5635(c)."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each share of Series X1 Convertible Preferred Stock will be convertible into 1,000 shares of Common Stock upon receipt of the requisite approval of the stockholders of the Issuer."}],"balance_after":5907.15,"derivative":{"exercise_price":500,"expiration_date":"2030-09-11","underlying":"Series X1 Convertible Preferred Stock","underlying_shares":5907.15},"source":{"system":"sec-edgar","filing":"0000899243-20-025166","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404281/000089924320025166/doc4.xml","form_type":"4"}},{"id":3147592,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":49925,"kind":"person","name":"Katkin Keith","position":1,"cik":"0001314596","reported_name":"Katkin Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-05-16T00:55:40.000Z","date":"2020-05-15","kind":"grant","acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares vest monthly over one (1) year from the date of grant subject to the reporting person's continuous service on the Company's Board of Directors."}],"balance_after":55000,"derivative":{"exercise_price":1.765,"expiration_date":"2030-05-15","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0001179110-20-006134","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000117911020006134/edgar.xml","form_type":"4"}},{"id":3256005,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":49925,"kind":"person","name":"Katkin Keith","position":1,"cik":"0001314596","reported_name":"Katkin Keith","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PEO;CEO/Urovant Sciences, Inc."}}],"security":"Stock Option (Right to Buy)","published_at":"2020-02-21T23:42:57.000Z","date":"2020-02-19","kind":"exercise","acquired":true,"shares":180000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"All of the shares underlying this option are vested and exercisable as of the date hereof."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Following the reported transactions, the Reporting Person beneficially owns options to purchase an aggregate of 1,416,166 common shares (inclusive of the options reported in Table II, Column 9 above)."}],"balance_after":701254,"derivative":{"exercise_price":3.86,"expiration_date":"2027-09-21","underlying":"Common Shares","underlying_shares":180000},"source":{"system":"sec-edgar","filing":"0000899243-20-005517","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1314596/000089924320005517/doc4.xml","form_type":"4"}},{"id":3256004,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":49925,"kind":"person","name":"Katkin Keith","position":1,"cik":"0001314596","reported_name":"Katkin Keith","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PEO;CEO/Urovant Sciences, Inc."}}],"security":"Common Shares","published_at":"2020-02-21T23:42:57.000Z","date":"2020-02-19","kind":"other","acquired":false,"shares":75212,"price":13.08,"value":983772.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the sale of 75,212 shares of common stock to Sumitovant Biopharma Ltd., a subsidiary of Dainippon Sumitomo Pharma, in a privately-negotiated transaction."}],"balance_after":199680,"source":{"system":"sec-edgar","filing":"0000899243-20-005517","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1314596/000089924320005517/doc4.xml","form_type":"4"}},{"id":3256003,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":49925,"kind":"person","name":"Katkin Keith","position":1,"cik":"0001314596","reported_name":"Katkin Keith","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PEO;CEO/Urovant Sciences, Inc."}}],"security":"Common Shares","published_at":"2020-02-21T23:42:57.000Z","date":"2020-02-19","kind":"tax_withholding","acquired":false,"shares":104788,"price":13.08,"value":1370627.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents 53,119 shares surrendered to the Issuer in satisfaction of payment of exercise price and 51,669 shares surrendered to the Issuer in satisfaction of the payment of required withholding taxes in connection with the exercise of stock options."}],"balance_after":274892,"source":{"system":"sec-edgar","filing":"0000899243-20-005517","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1314596/000089924320005517/doc4.xml","form_type":"4"}},{"id":3256002,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":49925,"kind":"person","name":"Katkin Keith","position":1,"cik":"0001314596","reported_name":"Katkin Keith","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PEO;CEO/Urovant Sciences, Inc."}}],"security":"Common Shares","published_at":"2020-02-21T23:42:57.000Z","date":"2020-02-19","kind":"exercise","acquired":true,"shares":180000,"price":3.86,"value":694800.0,"ownership":{"direct":true},"balance_after":379680,"source":{"system":"sec-edgar","filing":"0000899243-20-005517","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314596/000089924320005517/doc4.xml","form_type":"4"}},{"id":3270149,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":49925,"kind":"person","name":"Katkin Keith","position":1,"cik":"0001314596","reported_name":"Katkin Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-02-14T21:35:31.000Z","date":"2020-02-12","kind":"grant","acquired":true,"shares":24000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":24000,"derivative":{"exercise_price":9.47,"exercise_date":"2021-02-12","expiration_date":"2030-02-12","underlying":"Common Stock","underlying_shares":24000},"source":{"system":"sec-edgar","filing":"0001562180-20-001231","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314596/000156218020001231/primarydocument.xml","form_type":"4"}},{"id":3314371,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":49925,"kind":"person","name":"Katkin Keith","position":1,"cik":"0001314596","reported_name":"Katkin Keith","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PEO;CEO/Urovant Sciences, Inc."}}],"security":"Common Shares","published_at":"2020-01-09T21:33:02.000Z","date":"2020-01-07","kind":"grant","acquired":true,"shares":199680,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"25% of the Restricted Stock Units shall vest on January 7, 2021; the remaining Restricted Stock Units vest in 12 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer through each such vesting date."}],"balance_after":199680,"source":{"system":"sec-edgar","filing":"0000899243-20-000884","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314596/000089924320000884/doc4.xml","form_type":"4"}},{"id":3344977,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":49925,"kind":"person","name":"Katkin Keith","position":1,"cik":"0001314596","reported_name":"Katkin Keith","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PEO;CEO/Urovant Sciences, Inc."}}],"security":"Stock Option (Right to Buy)","published_at":"2019-12-11T22:01:12.000Z","date":"2019-12-09","kind":"exercise","acquired":false,"shares":120000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the total shares underlying the option vested and became exercisable on September 21, 2018; the remaining shares vest in 12 equal quarterly installments over the following three years, subject to the Reporting Person providing continuous service to the Issuer through each such vesting date."}],"balance_after":881254,"derivative":{"exercise_price":3.86,"expiration_date":"2027-09-21","underlying":"Common Shares","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0000899243-19-028937","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1314596/000089924319028937/doc4.xml","form_type":"4"}},{"id":3344976,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":49925,"kind":"person","name":"Katkin Keith","position":1,"cik":"0001314596","reported_name":"Katkin Keith","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PEO;CEO/Urovant Sciences, Inc."}}],"security":"Common Shares","published_at":"2019-12-11T22:01:12.000Z","date":"2019-12-09","kind":"sale","acquired":false,"shares":120000,"price":12.78,"value":1533600.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $12.35 to $12.885. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This transaction was executed to minimize the potential impact of 280G excise tax, which may be triggered by the change of control resulting from the acquisition by Sumitomo Dainippon Pharma Co., Ltd. of Roivant Sciences Ltd.'s ownership interest in the Issuer. Following the reported transaction, the Reporting Person beneficially owns options to purchase an aggregate of 1,596,166 common shares."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-19-028937","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1314596/000089924319028937/doc4.xml","form_type":"4"}},{"id":3344975,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":49925,"kind":"person","name":"Katkin Keith","position":1,"cik":"0001314596","reported_name":"Katkin Keith","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PEO;CEO/Urovant Sciences, Inc."}}],"security":"Common Shares","published_at":"2019-12-11T22:01:12.000Z","date":"2019-12-09","kind":"exercise","acquired":true,"shares":120000,"price":3.86,"value":463200.0,"ownership":{"direct":true},"balance_after":120000,"source":{"system":"sec-edgar","filing":"0000899243-19-028937","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314596/000089924319028937/doc4.xml","form_type":"4"}},{"id":3461864,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":49925,"kind":"person","name":"Katkin Keith","position":1,"cik":"0001314596","reported_name":"Katkin Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-07-15T20:05:49.000Z","date":"2019-07-11","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":20000,"derivative":{"exercise_price":0.88,"exercise_date":"2020-07-11","expiration_date":"2029-07-11","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000899243-19-019600","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404281/000089924319019600/doc4.xml","form_type":"4"}},{"id":3492422,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":49925,"kind":"person","name":"Katkin Keith","position":1,"cik":"0001314596","reported_name":"Katkin Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-12T13:00:39.000Z","date":"2019-06-10","kind":"grant","acquired":true,"shares":24000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":24000,"derivative":{"exercise_price":7.88,"exercise_date":"2020-06-10","expiration_date":"2029-06-10","underlying":"Common Stock","underlying_shares":24000},"source":{"system":"sec-edgar","filing":"0001562180-19-003489","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314596/000156218019003489/primarydocument.xml","form_type":"4"}},{"id":3512129,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":49925,"kind":"person","name":"Katkin Keith","position":1,"cik":"0001314596","reported_name":"Katkin Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-05-24T21:23:03.000Z","date":"2019-05-23","kind":"grant","acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares shall vest monthly over one (1) year from the date of grant subject to the reporting person's continuous service on the Company's Board of Directors."}],"balance_after":55000,"derivative":{"exercise_price":2.02,"expiration_date":"2029-05-23","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0001179110-19-006703","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000117911019006703/edgar.xml","form_type":"4"}},{"id":3699955,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":49925,"kind":"person","name":"Katkin Keith","position":1,"cik":"0001314596","reported_name":"Katkin Keith","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PEO;CEO/Urovant Sciences, Inc."}}],"security":"Stock Option (Right to Buy)","published_at":"2019-01-08T22:22:49.000Z","date":"2019-01-06","kind":"grant","acquired":true,"shares":350250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the total shares underlying the option shall vest and become exercisable on January 2, 2020; the remaining shares vest in 12 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer through each such vesting date."}],"balance_after":350250,"derivative":{"exercise_price":6.88,"expiration_date":"2029-01-06","underlying":"Common Shares","underlying_shares":350250},"source":{"system":"sec-edgar","filing":"0000899243-19-000777","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314596/000089924319000777/doc4.xml","form_type":"4"}},{"id":3788006,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":49925,"kind":"person","name":"Katkin Keith","position":1,"cik":"0001314596","reported_name":"Katkin Keith","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PEO;CEO-Urovant Sciences,Inc."}}],"security":"Stock Option (Right to Buy)","published_at":"2018-10-17T22:12:43.000Z","date":"2018-10-15","kind":"grant","acquired":true,"shares":99967,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the total shares underlying the option shall vest and become exercisable on October 1, 2019; the remaining shares vest in 12 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer through each such vesting date."}],"balance_after":99967,"derivative":{"exercise_price":13.65,"expiration_date":"2028-10-14","underlying":"Common Shares","underlying_shares":99967},"source":{"system":"sec-edgar","filing":"0001209191-18-055417","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314596/000120919118055417/doc4.xml","form_type":"4"}},{"id":3798137,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":49925,"kind":"person","name":"Katkin Keith","position":1,"cik":"0001314596","reported_name":"Katkin Keith","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PEO;CEO-Urovant Sciences,Inc."}}],"security":"Stock Option (Right to Buy)","published_at":"2018-10-04T01:04:28.000Z","date":"2018-10-01","kind":"grant","acquired":true,"shares":200250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price of this option is $3.86. In light of the performance-based vesting condition of this option grant, such option grant was not reportable under Section 16 until the performance-based vesting condition was satisfied. The performance-based vesting condition was satisfied on October 1, 2018."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to the achievement of the Issuer's performance measurement referred to in Footnote (1) herein on October 1, 2018, 25% of the total shares underlying the option shall vest and become exercisable on October 1, 2019; the remaining shares vest in 12 equal quarterly installments over the following three years, subject to the Reporting Person providing continuous service to the Issuer through each such vesting date."}],"balance_after":200250,"derivative":{"exercise_price":3.86,"expiration_date":"2027-09-21","underlying":"Common Shares","underlying_shares":200250},"source":{"system":"sec-edgar","filing":"0001209191-18-054162","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314596/000120919118054162/doc4.xml","form_type":"4"}},{"id":3805440,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":49925,"kind":"person","name":"Katkin Keith","position":1,"cik":"0001314596","reported_name":"Katkin Keith","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PEO;CEO-Urovant Sciences,Inc."}}],"security":"Stock Option (Right to Buy)","published_at":"2018-09-28T20:10:10.000Z","date":"2018-09-26","kind":"grant","acquired":true,"shares":39815,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the total shares underlying the option shall vest and become exercisable on September 26, 2019; the remaining shares vest in 12 equal quarterly installments over the following three years, subject to the Reporting Person providing continuous service to the Issuer through each such vesting date."}],"balance_after":39815,"derivative":{"exercise_price":14,"expiration_date":"2028-09-25","underlying":"Common Shares","underlying_shares":39815},"source":{"system":"sec-edgar","filing":"0001209191-18-052549","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314596/000120919118052549/doc4.xml","form_type":"4"}},{"id":3893667,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":49925,"kind":"person","name":"Katkin Keith","position":1,"cik":"0001314596","reported_name":"Katkin Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-06-14T21:52:48.000Z","date":"2018-06-13","kind":"grant","acquired":true,"shares":9100,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":9100,"derivative":{"exercise_price":6.18,"exercise_date":"2019-06-13","expiration_date":"2028-06-13","underlying":"Common Stock","underlying_shares":9100},"source":{"system":"sec-edgar","filing":"0000899243-18-016653","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404281/000089924318016653/doc4.xml","form_type":"4"}},{"id":3916790,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":49925,"kind":"person","name":"Katkin Keith","position":1,"cik":"0001314596","reported_name":"Katkin Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-05-25T13:00:05.000Z","date":"2018-05-23","kind":"grant","acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":14000,"derivative":{"exercise_price":8.93,"exercise_date":"2019-05-23","expiration_date":"2028-05-23","underlying":"Common Stock","underlying_shares":14000},"source":{"system":"sec-edgar","filing":"0001562180-18-002682","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314596/000156218018002682/primarydocument.xml","form_type":"4"}},{"id":3926186,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":49925,"kind":"person","name":"Katkin Keith","position":1,"cik":"0001314596","reported_name":"Katkin Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-05-19T01:28:31.000Z","date":"2018-05-17","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares shall vest monthly over one (1) year from the date of grant subject to the reporting person's continuous service on the Company's Board of Directors."}],"balance_after":40000,"derivative":{"exercise_price":3.98,"expiration_date":"2028-05-17","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001179110-18-007149","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000117911018007149/edgar.xml","form_type":"4"}},{"id":4065747,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":49925,"kind":"person","name":"Katkin Keith","position":1,"cik":"0001314596","reported_name":"Katkin Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-02-12T21:01:03.000Z","date":"2018-02-08","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36th of the shares subject to the option shall vest monthly over a three-year period."}],"balance_after":10000,"derivative":{"exercise_price":9.63,"expiration_date":"2028-02-08","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001562180-18-000721","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314596/000156218018000721/primarydocument.xml","form_type":"4"}},{"id":4263980,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":49925,"kind":"person","name":"Katkin Keith","position":1,"cik":"0001314596","reported_name":"Katkin Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-07-05T20:05:34.000Z","date":"2017-06-30","kind":"grant","acquired":true,"shares":36000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 36,000 shares of the Issuer's Common Stock. The shares will vest ratably each quarter over three years beginning on June 30, 2017."}],"balance_after":36000,"derivative":{"exercise_price":5.85,"expiration_date":"2027-06-30","underlying":"Common Stock","underlying_shares":36000},"source":{"system":"sec-edgar","filing":"0000899243-17-017760","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404281/000089924317017760/doc4.xml","form_type":"4"}},{"id":4311517,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":49925,"kind":"person","name":"Katkin Keith","position":1,"cik":"0001314596","reported_name":"Katkin Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-05-19T15:26:45.000Z","date":"2017-05-17","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":10000,"derivative":{"exercise_price":13.58,"exercise_date":"2018-05-17","expiration_date":"2027-05-17","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001562180-17-002007","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314596/000156218017002007/primarydocument.xml","form_type":"4"}},{"id":4323101,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":49925,"kind":"person","name":"Katkin Keith","position":1,"cik":"0001314596","reported_name":"Katkin Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-05-12T22:01:33.000Z","date":"2017-05-12","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares vest monthly over twelve (12) months from the date of grant."}],"balance_after":40000,"derivative":{"exercise_price":2.61,"expiration_date":"2027-05-12","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001179110-17-007132","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000117911017007132/edgar.xml","form_type":"4"}},{"id":4366597,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":49925,"kind":"person","name":"Katkin Keith","position":1,"cik":"0001314596","reported_name":"Katkin Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-03-31T20:46:13.000Z","date":"2017-03-29","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36th of the shares subject to the option shall vest monthly over a three-year period."}],"balance_after":25000,"derivative":{"exercise_price":13.78,"expiration_date":"2027-03-29","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001562180-17-001365","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314596/000156218017001365/primarydocument.xml","form_type":"4"}}]}